Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

TRINOVA-3/ENGOT-ov2/GOG-3001 investigators

Research output: Contribution to journalArticle

21 Scopus citations

Fingerprint Dive into the research topics of 'Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences